Browser does not support script.
Skip to main content
Where access to drug treatments is concerned, it is notable that the smaller the population affected by a particular cancer the fewer treatments there are available and the more difficult it is for NICE to evaluate the treatments due to lack of evidence.
Furthermore, many patients experience emotional and practical difficulties as a result of not being able to access effective treatments, especially when they have participated in the exceptional case procedure.
In a session drawing on the All Party Parliamentary Group on Cancer’s Inquiry report recommendations around promoting fairer access to drug treatments, attendees were asked whether the APPGC has got it right when it comes to NICE reform and what more could realistically be done to ensure all cancer patients get speedy access to clinically effective drug treatments available throughout the rest of Europe.
View Catherine Foot's presentation [PDF, 222kb] |
Breakout session two: Research and technologies
If you have any questions about Macmillan we would love to hear from you| .
You can also follow us| on Facebook, Twitter, Flickr or YouTube.
© Macmillan Cancer Support 2013
what are these?|